Metronomic Chemotherapy With Tegafur/Uracil for Head and Neck Squamous Cell Carcinoma

• Status: Unknown status
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

It is the investigators understanding that the combination of clinical trial with laboratory cellular/molecular assay is relevant to the current promising mainstream, the translational research. The design of this trial fulfills this concept and would be a good example conducting in Mackay Memorial hospital.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mackay Memorial Hospital
• Treatments: Tegafur

Criteria

Inclusion Criteria:

• Histologically confirmed non-nasopharyngeal head and neck squamous cell carcinoma

• Complete response(CR) to previous treatment

• White blood cell (WBC) count greater than 3,000/mm3 and absolute neutrophil count (ANC) greater than 1,500/mm3, and platelets greater than 50,000/mm3

• Serum bilirubin less than 2 times the upper limit of normal range (ULN)

• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST)

• Serum creatinine less than 2.0 times the ULN

• ECOG performance status 0, 1, 2

• Age, 20 years or older

Exclusion Criteria:

• Other malignancy, with the exception of curatively treated non-melanoma skin cancer or cervical carcinoma in situ prior to commencement of the study

• CR was confirmed more than 6 weeks prior to commencement of the study

• Concurrent treatment which may interfere with evaluation

• Pregnancy or breast feeding